 | |||||||
| technology | |||||||
| NEWS | |||||||
Searching for Synergy in Liver-Dominant Neuroendocrine Tumors The addition of radioembolization to a combination of capecitabine (Xeloda) and temozolomide (Temodar) as radiosensitizing chemotherapy may improve efficacy outcomes for patients with liver-dominant neuroendocrine tumors (NETs), according to Michael C.
| |||||||
| See more results | Edit this alert | |||||||
| You have received this email because you have subscribed to Google Alerts. |
 Receive this alert as RSS feed |
| Send Feedback |
No comments:
Post a Comment